Literature DB >> 8882302

Drug monitoring in nonconventional biological fluids and matrices.

S Pichini1, I Altieri, P Zuccaro, R Pacifici.   

Abstract

Determination of the concentration of drugs and metabolites in biological fluids or matrices other than blood or urine (most commonly used in laboratory testing) may be of interest in certain areas of drug concentration monitoring. Saliva is the only fluid which can be used successfully as a substitute for blood in therapeutic drug monitoring, while an individual's past history of medication, compliance and drug abuse, can be obtained from drug analysis of the hair or nails. Drug concentrations in the bile and faeces can account for excretion of drugs and metabolites other than by the renal route. Furthermore, it is important that certain matrices (tears, nails, cerebrospinal fluid, bronchial secretions, peritoneal fluid and interstitial fluid) are analysed, as these may reveal the presence of a drug at the site of action; others (fetal blood, amniotic fluid and breast milk) are useful for determining fetal and perinatal exposure to drugs. Finally, drug monitoring in fluids such as cervical mucus and seminal fluid can be associated with morpho-physiological modifications and genotoxic effects. Drug concentration measurement in nonconventional matrices and fluids, although sometimes expensive and difficult to carry out, should therefore be considered for inclusion in studies of the pharmacokinetics and pharmacodynamics of new drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882302     DOI: 10.2165/00003088-199630030-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  126 in total

1.  Excretion of phenytoin into semen of rabbits and man. Comparison with plasma levels.

Authors:  B N Swanson; R M Leger; W P Gordon; R K Lynn; N Gerber
Journal:  Drug Metab Dispos       Date:  1978 Jan-Feb       Impact factor: 3.922

Review 2.  The role of saliva in drug monitoring.

Authors:  I A Siegel
Journal:  Ann N Y Acad Sci       Date:  1993-09-20       Impact factor: 5.691

3.  Secretion of drugs in tears.

Authors:  N J van Haeringen
Journal:  Curr Eye Res       Date:  1985-04       Impact factor: 2.424

4.  Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis.

Authors:  P Somani; R S Shapiro; H Stockard; J T Higgins
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

5.  Plasma and skin blister fluid levels of cefotiam and cefmenoxime after single intramuscular application of 1 g in gonorrhea.

Authors:  H C Korting
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

6.  Identification of oxidation products of 5-aminosalicylic acid in faeces and the study of their formation in vitro.

Authors:  J Jensen; C Cornett; C E Olsen; S Bondesen; J Christensen; L A Christensen; J Tjørnelund; S H Hansen
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

7.  Transcutaneous theophylline collection in preterm infants.

Authors:  M G Murphy; C C Peck; D P Conner; K Zamani; G B Merenstein; D Rodden
Journal:  Clin Pharmacol Ther       Date:  1990-04       Impact factor: 6.875

8.  Transfer of penicillin G and ampicillin into human skin blisters induced by suction.

Authors:  A Schreiner; K B Hellum; A Digranes; I Bergman
Journal:  Scand J Infect Dis Suppl       Date:  1978

Review 9.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  Opiate concentrations in human head, axillary, and pubic hair.

Authors:  P Kintz; P Mangin
Journal:  J Forensic Sci       Date:  1993-05       Impact factor: 1.832

View more
  22 in total

Review 1.  Drugs in nails: physiology, pharmacokinetics and forensic toxicology.

Authors:  A Palmeri; S Pichini; R Pacifici; P Zuccaro; A Lopez
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  Clinical metabolomics: the next stage of clinical biochemistry.

Authors:  Angelo D'Alessandro; Bruno Giardina; Federica Gevi; Anna Maria Timperio; Lello Zolla
Journal:  Blood Transfus       Date:  2012-05       Impact factor: 3.443

3.  Meconium as a matrix.

Authors:  L M Stolk
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 4.  Best practice in therapeutic drug monitoring.

Authors:  A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 5.  A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.

Authors:  Tony K L Kiang; Urs O Häfeli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

6.  Investigation of the Association Between Total and Free Plasma and Saliva Mycophenolic Acid Concentrations Following Administration of Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients.

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Brett McWhinney; Christine E Staatz
Journal:  Clin Drug Investig       Date:  2019-12       Impact factor: 2.859

7.  Optimization of the weck-Cel collection method for quantitation of cytokines in mucosal secretions.

Authors:  L C Rohan; R P Edwards; L A Kelly; K A Colenello; F P Bowman; P A Crowley-Nowick
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

8.  The authors reply.

Authors:  S Pichini; I Altieri; R Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

9.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

10.  Reverse iontophoresis as a noninvasive tool for lithium monitoring and pharmacokinetic profiling.

Authors:  Benoît Leboulanger; Marc Fathi; Richard H Guy; M Begoña Delgado-Charro
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.